DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM)
and is based on promoting the incretin effect. Here, the authors have presented a brief …

The metabolic syndrome as a consequence of the obesity pandemic resulted in a
substantial increase in the prevalence of metabolic-associated fatty live disease (MAFLD) …

The incretin hormone glucagon-like peptide 1 (GLP-1) is a key component of the signaling
mechanisms promoting glucose homeostasis. Clinical and experimental studies …

Lipopeptides are surface active, natural products of bacteria, fungi and green-blue algae
origin, having diverse structures and functionalities. In analogy, a number of chemical …

Cluster of differentiation 26 (CD26)/dipeptidyl peptidase 4 (DPP4) is an exopeptidase that is
expressed as a transmembrane protein in many organs but also present in a circulating …

The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people
with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising …

Abstract Glucagon‐like peptide‐1 (GLP‐1)‐based medication is now widely employed in the
treatment of type 2 diabetes and obesity. Like other gut hormones, GLP‐1 is released from …

Abstract Dipeptidyl peptidase-4 (DPP4) inhibitors are a potent therapeutic treatment for type
2 diabetes mellitus (T2DM). There is a family of compounds used as DPP4 inhibitors …

Protein intake potently increases body temperature and energy expenditure, but the
underlying mechanism thereof remains incompletely understood. Simultaneously, protein …

Background There are increasing data on the potential risk of pancreatic carcinoma
associated with glucagon-like peptide 1 receptor agonists (GLP-1RAs). Aim The study …